ReviewWorld journal of gastroenterology2022
Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Hepatitis B virus prevalence, susceptibility and care engagement among vulnerable migrant populations in Rome.BMC infectious diseases · 2026Article
- Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B.World journal of gastrointestinal surgery · 2025Article
- Screening for infectious and neglected tropical diseases among newly arrived migrants from Africa and Asia: a retrospective study from Verona province, Italy.Tropical medicine and health · 2025Article
- Regional assessment is useful for identifying populations at high-risk of hepatitis B virus transmission: A nationwide analysis of population-based surveillance including the COVID-19 pandemic era.Global health & medicine · 2025Article
- Immune Escape and Drug Resistance Mutations in Patients with Hepatitis B Virus Infection: Clinical and Epidemiological Implications.Life (Basel, Switzerland) · 2025Article
- HBV and HCV testing outcomes among marginalized communities in Italy, 2019-2024: a prospective study.The Lancet regional health. Europe · 2025Article
- Review of Albanian studies suggests the need for further efforts to counteract significant hepatitis B virus prevalence.World journal of virology · 2024Article
- Effectiveness of a Counseling Intervention to Increase Vaccination Uptake among Men Who Have Sex with Men during the Mpox Outbreak.Vaccines · 2024Article
- Current perspectives of viral hepatitis.World journal of gastroenterology · 2024Review
- HBV in Italian Women's Jail: An Underestimated Problem?Journal of clinical medicine · 2024Article
- Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland.Clinical and experimental hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A relevant gradual reduction of both the incidence rate of acute hepatitis B (AHB) and prevalence of chronic hepatitis B has occurred in Italy in the last 50 years, due to substantial epidemiological changes: Improvement in socioeconomic and hygienic conditions, reduction of the family unit, accurate screening of blood donations, abolition of re-usable glass syringes, hepatitis B virus (HBV)-universal vaccination started in 1991, use of effective well tolerated nucleo(t)side analogues able to suppress HBV replication available from 1998, and educational mediatic campaigns against human immunodeficiency virus infection focusing on the prevention of sexual and parenteral transmission of infections. As an example, AHB incidence has gradually decreased from 10/100000 inhabitants in 1985 to 0.21 in 2020. Unfortunately, the coronavirus disease 2019 (COVID-19) pandemic has interrupted the trend towards HBV eradication. In fact, several HBV chronic carriers living in the countryside have become unable to access healthcare facilities for screening, diagnosis, clinical management, and nucleo(t)side analogue therapy in the COVID-19 pandemic, mainly for anxiety of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), movement restrictions, and reduced gains from job loss. In addition, one-third of healthcare facilities and personnel for HBV patients have been devolved to the COVID-19 assistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.